Originally developed for type 2 diabetes and subsequently used to treat obesity, glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly being investigated for a wide range of conditions far removed from metabolism. According to Peterattiamd, these therapies have already earned approvals for cardiovascular disease, chronic kidney disease, obstructive sleep apnea, and metabolic liver disease. As the list of potential indications grows, researchers are examining how much of the therapeutic effect stems from distinct biological pathways versus standard metabolic improvements like weight loss and glycemic control.
Expanding Horizons for GLP-1 Medications
Innovations such as oral GLP-1 formulations could further accelerate accessibility and uptake, potentially expanding the user base to include non-obese and older populations, according to a report by Foodnavigator. This potential shift is drawing close attention from food and beverage companies aiming to understand changing consumer behavior, consumption patterns, and nutritional needs.
Clinical Trials Targeting Alcohol Use and Liver Disease
In the United Kingdom, researchers are launching a clinical trial to explore whether semaglutide—marketed as Wegovy—can help patients affected by alcohol dependency, obesity, and liver disease. As reported by Lboro, alcohol use is a leading cause of death in the UK and its main cause of liver disease, with about half of those living with alcohol-related liver disease also being obese.
Starting in September 2026, the CURB trial will recruit 268 participants with alcohol dependence, obesity, and chronic liver disease across England, Wales, and Scotland. Over 36 weeks, participants will receive either semaglutide or a dummy treatment to assess whether the drug can reduce alcohol consumption and improve weight, liver health, and quality of life.
Additional observational research noted by Dongascience found that participants given GLP-1 drugs exhibited a slower rise in breath alcohol concentration and reported feeling less intoxicated after consuming a fixed amount of alcohol, though researchers caution that randomized clinical trials are required to confirm these effects.
Emerging Research in Oncology and Ageing
Oncological research involving GLP-1 medications was featured at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, according to Foodnavigator. An analysis of more than 110,000 women indicated that those taking GLP-1s were 30% less likely to develop breast cancer, prompting the design of a prospective clinical trial to test prevention capabilities. Lead author Professor Elizabeth McDonald noted that while the observational results cannot confirm causality, they add to a growing body of evidence supporting further investigation.
A second observational study of more than 12,000 health records associated GLP-1 use with a lower risk of tumor spread in lung, breast, colorectal, and liver cancers by nearly 40% to 50% compared with older drugs called gliptins. Professor Marcin Chwistek of the Fox Chase Cancer Center stated that robust clinical trials will be necessary before these drugs might be repurposed on a wider scale.
Additionally, research tracking cellular ageing found that individuals treated with semaglutide displayed slower biological aging across inflammation, heart, and brain ageing measures, pointing toward potential applications in gerotherapeutics.
